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Introduction {#sec007}
============

Multimorbidity, the presence of two or more chronic conditions \[[@pmed.1003094.ref001]\], is the norm in people with type 2 diabetes (T2D). Approximately 85% of people with T2D have at least one other chronic condition \[[@pmed.1003094.ref002]\], making multimorbidity in this population an important clinical and public health priority. Multimorbidity brings many challenges, including difficulties in managing the competing demands of multiple conditions. Self-management of any chronic condition can be burdensome, and those with multimorbidity are likely to experience greater levels of treatment burden because of the complex self-management requirements imposed by different conditions \[[@pmed.1003094.ref003]\]. This can result in reduced adherence to complicated therapeutic regimens and poorer outcomes \[[@pmed.1003094.ref004]\]. For people with T2D, this could lead to suboptimal glycaemic management, which has been shown to result in the development of complications and increased mortality \[[@pmed.1003094.ref005],[@pmed.1003094.ref006]\].

Currently, there is no universally accepted measure of multimorbidity. Despite this, studies using a range of different methodologies in varying study settings consistently show that multimorbidity in people with T2D is associated with higher risk of death \[[@pmed.1003094.ref007]\]. However, only one study attempted to assess the influence of type of condition included in their multimorbidity count by differentiating between physical and mental health condition counts \[[@pmed.1003094.ref008]\]. This resonates with the wider multimorbidity literature, which suggests that type as well as number of conditions is important \[[@pmed.1003094.ref001]\]. Piette and Kerr have suggested that multiple conditions in those with T2D should be qualitatively assessed as concordant or discordant \[[@pmed.1003094.ref005]\]. Concordant conditions are closely related to T2D and represent parts of the same overall pathophysiologic risk profile and are more likely to be the focus of the same disease and management plan (e.g., hypertension), whereas discordant conditions are not directly related in either their pathogenesis or management (e.g., depression, osteoarthritis, and cancer) \[[@pmed.1003094.ref005]\].

Although the associations between multimorbidity, glycated haemoglobin (HbA1c) \[[@pmed.1003094.ref007],[@pmed.1003094.ref009]\], and all-cause mortality \[[@pmed.1003094.ref007],[@pmed.1003094.ref008],[@pmed.1003094.ref010]\] in people with T2D have been studied to some extent, significant gaps remain in the existing literature, particularly regarding different patterns of multimorbidity, including concordant and discordant conditions, and their associations with HbA1c and mortality. This study addresses this evidence gap and aims to assess the associations between different counts of multimorbidity, including concordant and discordant conditions, on HbA1c and all-cause mortality in people with T2D. We also aim to understand whether associations between multimorbidity and our outcomes are universally consistent across separate cohorts from two countries with different healthcare systems and differing ethnicities, using data from the UK Biobank (a large community cohort of more than half a million people across the United Kingdom) \[[@pmed.1003094.ref011]\] and the Taiwan National Diabetes Care Management Program (NDCMP) (a large cohort of people with T2D across Taiwan) \[[@pmed.1003094.ref012]\].

Methods {#sec008}
=======

Study design and participants {#sec009}
-----------------------------

Two large community cohorts were used in this study. The UK Biobank (described elsewhere) \[[@pmed.1003094.ref011]\] includes 502,640 participants recruited between 2006 and 2010, with linkage to routine healthcare data until 2018. We identified 20,569 people with T2D using a published algorithm developed by Eastwood and colleagues \[[@pmed.1003094.ref013]\], which has been validated externally using primary and secondary care hospital data linked to the UK Biobank \[[@pmed.1003094.ref013]\]. All 20,569 people with T2D in the UK Biobank were included in the statistical analysis.

The Taiwan NDCMP (described elsewhere) \[[@pmed.1003094.ref012]\] includes 63,084 ethnic Chinese participants with any type of diabetes recruited between 2001 and 2004 and followed until 2011. We excluded those with type 1 diabetes and gestational diabetes. In the final analysis, 59,657 people with T2D from the Taiwan NDCMP were included.

Ethics approvals were granted by the NHS National Research Ethics Service (generic ethics approval for UK Biobank studies, approval letter dated 17 June 2011, Ref 11/NW/0382), the China Medical University Hospital Ethical Review Board (CMUH106-REC1-148), and the University of Melbourne Human Research Ethics Committee (Ethic ID: 1851038.1). Our detailed study protocol is shown in [S1 Text](#pmed.1003094.s001){ref-type="supplementary-material"}, and we have adhered to the STROBE statement (see [S2 Text](#pmed.1003094.s002){ref-type="supplementary-material"}).

Procedures {#sec010}
----------

We classified multimorbidity on the basis of a count of 42 chronic conditions in addition to T2D based on previously published literature (see [S1 Table](#pmed.1003094.s003){ref-type="supplementary-material"}) \[[@pmed.1003094.ref001]\]. In the UK Biobank, conditions were identified using self-reported conditions from the nurse-led interview as well as using linkage to Hospital Episode Statistics (HES). Participants were considered to have a condition if it was either self-reported or if they had relevant International Classification of Disease (ICD)-10-CM codes from a hospital episode occurring prior to the assessment centre date. In the Taiwan NDCMP, conditions were identified using ICD-9-CM codes to search hospital data from inpatient care and outpatient visits including primary care. We qualitatively assessed each of the comorbid conditions and categorised these as either concordant or discordant based on Piette and Kerr's \[[@pmed.1003094.ref005]\] definitions mentioned previously. We presented multimorbidity in three ways: total, concordant, and discordant condition counts. Each of the counts were categorised into zero, one, two, three, or four or more conditions (in addition to T2D).

In both datasets, age, body mass index (BMI), duration of diabetes, and baseline HbA1c were used as continuous variables. Sex and use of corticosteroids were used as categorical variables. Use of glucose-lowering drugs was classified into no medication, one noninsulin antidiabetic drug (oral antidiabetes drug \[OAD\]), two OADs, three OADs, more than three OADs, insulin only, or insulin and OAD.

In the UK Biobank, socioeconomic status was classified into quintiles based on Townsend score (an area-based measure of deprivation in the UK) on the whole UK Biobank \[[@pmed.1003094.ref014]\]: category 1 was the least deprived, and category 5 was the most deprived category. Smoking status was classified into two categories: yes (current) or no. Alcohol intake was based on self-reported frequency of alcohol intake: never or special occasions only, one to three times per month, one to four times per week, or daily. Physical activity was self-reported based on responses from the UK Biobank physical activity questionnaire. We categorised the responses into none (no physical activity in the last 4 weeks), low (light activity \[e.g., pruning, watering the lawn\] only in the last 4 weeks), medium (heavy activity \[e.g., weeding, lawn mowing, carpentry, and digging\] and/or walking for pleasure and/or other exercises in the last 4 weeks), or high (strenuous sports in the last 4 weeks). Data on physical activity were only available in the UK Biobank dataset.

In the Taiwan NDCMP, socioeconomic status was measured by amount of health insurance premium, insured unit, and residential area. Smoking status and alcohol consumption were classified into two categories: yes (current) or no. Number of outpatient visits was used as a continuous variable and was only available in the Taiwan NDCMP dataset.

Outcome {#sec011}
-------

There were two outcomes of interest: baseline HbA1c and all-cause mortality. We explored the cross-sectional association between multimorbidity counts and the most recent HbA1c measure collected at time of recruitment. In contrast, the association between multimorbidity counts and all-cause mortality explored was longitudinal. In the UK Biobank, all-cause mortality data were from the national mortality records linked by the UK Biobank up to 2018. The median (IQR) follow-up duration was 8.8 years (97--104 months). In the Taiwan NDCMP, all participants were followed from time of entry into the study to 31 December 2011 or until death or withdrawal from the NDCMP. The median (IQR) follow-up duration was 8.8 years (98--110 months).

Statistical analysis {#sec012}
--------------------

Statistical analyses for the UK Biobank and the Taiwan NDCMP cohorts were conducted separately. Descriptive statistics summarised the overall characteristics of the participants and the prevalence of individual health conditions.

Multivariable linear regression models were used to compare baseline HbA1c between different categorical combinations of multimorbidity counts (total condition count, concordant condition count, discordant condition count). Adjustments were made for age, gender, BMI, smoking status, alcohol consumption, socioeconomic status, duration of diabetes, use of OADs, and use of corticosteroids.

Cumulative survival plots were used to compare cumulative survival between participants with T2D with different multimorbidity counts. This was done for total condition count, concordant condition count, and discordant condition count.

Multivariable Cox proportional hazards models were used to compare all-cause mortality between different categorical combinations of multimorbidity counts (total condition count, concordant condition count, discordant condition count). Adjustments made were the same as those described above plus baseline HbA1c.

Multivariable Cox proportional hazards models were fitted to each of the individual chronic conditions that had a prevalence of \>1% in our study population to examine their association with all-cause mortality.

Multivariable Cox proportional hazards models were fitted to all possible combinations of two conditions in addition to T2D to examine their association with all-cause mortality. We present the top 20 combinations in terms of hazard ratios (HRs).

For the UK Biobank, all analyses were performed using R software (version 3.4.1). Syntax for the generation of derived variables and for the analysis used for this study were submitted to UK Biobank for record. For the Taiwan NDCMP, all analyses were performed with the SAS statistical package for Windows (version 9.3, SAS; Cary, NC, United States).

Sensitivity analysis {#sec013}
--------------------

For the multivariable linear regression models on HbA1c and multivariable Cox proportional hazards models on mortality, we further adjusted for variables that were only available in each of the datasets. In the UK Biobank analyses, we additionally adjusted for physical activity, and for the Taiwan NDCMP, we additionally adjusted for number of outpatient visits.

For the multivariable linear regression models on HbA1c and multivariable Cox proportional hazards models on mortality in the UK Biobank, we reran the models using only HES data to identify multimorbidity.

Results {#sec014}
=======

In total, 20,569 and 59,657 people with T2D in the UK Biobank and the Taiwan NDCMP, respectively, were included in the study for analysis. In the UK Biobank, more than 90% of participants were multimorbid (having at least one chronic condition in addition to T2D), whereas approximately 80% of those in the Taiwan NDCMP were multimorbid. [Table 1](#pmed.1003094.t001){ref-type="table"} describes the overall characteristics of participants included in our study.

10.1371/journal.pmed.1003094.t001

###### Characteristics of participants with T2D.

![](pmed.1003094.t001){#pmed.1003094.t001g}

  UK Biobank (*N =* 20,569)                                       
  --------------------------------------------------------------- ------------------------
  **Age (years), mean (SD)**                                      60.2 (6.8)
  **Female, *n* (%)**                                             7,579 (36.8)
  **BMI (kg/m**^**2**^**), median (IQR)**                         30.8 (27.7, 34.8)
      Missing                                                     179
  **Smoking status, yes (current), *n* (%)**                      2,197 (10.8)
      Missing                                                     223
  **Alcohol frequency, *n* (%)**                                  
      Never                                                       7,154 (34.9)
      1--3 times per month                                        2,521 (12.3)
      1--4 times per week                                         7,851 (38.3)
      Daily                                                       2,946 (14.4)
      Missing                                                     97
  **Physical activity, *n* (%)**                                  
      None                                                        2,830 (14.1)
      Low                                                         1,209 (6.0)
      Medium                                                      15,322 (76.4)
      High                                                        684 (3.4)
      Missing                                                     524
  **Baseline HbA1c (%), mean (SD)**                               6.8 (1.2)
      Missing                                                     1,597
  **Duration of diabetes (years), median (IQR)**                  4 (2, 8)
  **Type of glucose-lowering drug use, *n* (%)**                  
      No medication                                               6,778 (33.0)
      1 OAD                                                       8,036 (39.1)
      2 OADs                                                      4,412 (21.4)
      3 OADs                                                      715 (3.5)
      \>3 OADs                                                    9 (0.0)
      Insulin + OAD                                               619 (3.0)
  **Use of corticosteroids, *n* (%)**                             203 (0.0)
  **Townsend score, *n* (%)**                                     
      Category 1---least deprived                                 2,993 (14.6)
      Category 2                                                  3,315 (16.1)
      Category 3                                                  3,687 (18.0)
      Category 4                                                  4,334 (21.1)
      Category 5---most deprived                                  6,209 (30.2)
      Missing                                                     31
  **Number of chronic conditions, *n* (%)**                       
      None                                                        1,918 (9.3)
      1                                                           5,114 (24.9)
      2                                                           5,109 (24.8)
      3                                                           3,643 (17.7)
      ≥4                                                          4,785 (23.3)
  **Taiwan NDCMP (*N =* 59,657)**                                 
  **Age (years), mean (SD)**                                      60.8 (11.3)
  **Female, *n* (%)**                                             31,339 (52.5)
  **BMI (kg/m**^**2**^**), median (IQR)**                         25.6 (23.5, 28.7)
      Missing                                                     1,376
  **Smoking status, yes (current), *n* (%)**                      9,423 (15.8)
      Missing                                                     45
  **Alcohol consumption, yes, *n* (%)**                           5,140 (8.6)
      Missing                                                     55
  **Baseline HbA1c (%), mean (SD)**                               8.2 (2.0)
      Missing                                                     276
  **Duration of diabetes (years), median (IQR)**                  5 (1, 9)
  **Type of glucose-lowering drug use, *n* (%)**                  
      No medication                                               1,880 (3.2)
      1 OAD                                                       10,714 (18.0)
      2 OADs                                                      24,401 (40.9)
      3 OADs                                                      10,361 (17.4)
      \>3 OADs                                                    3,000 (5.0)
      Insulin use                                                 1,719 (2.9)
      Insulin + OAD                                               7,582 (12.7)
  **Use of corticosteroids, *n* (%)**                             2,964 (5.0)
  **Urbanisation level, *n* (%)**                                 
      1---most deprived                                           12,495 (21.0)
      2                                                           18,962 (31.9)
      3                                                           10,504 (17.7)
      4                                                           11,735 (19.7)
      \>4---least deprived                                        5,808 (9.8)
      Missing                                                     153
  **Amount of insured premium (NTD\$ per month), median (IQR)**   21,900 (1,317, 31,800)
  **Insured unit, *n* (%)**                                       
      Government, school, or private enterprise employees         20,491 (34.5)
      Member of occupational, farmers, fishermen groups           24,625 (41.5)
      Low-income households and veterans                          14,206 (24.0)
      Missing                                                     335
  **Number of outpatient visits, mean (SD)**                      23.75 (15.4)
  **Number of chronic conditions, *n* (%)**                       
      None                                                        12,950 (21.7)
      1                                                           15,485 (26.0)
      2                                                           15,139 (25.4)
      3                                                           8,330 (14.0)
      ≥4                                                          7,753 (13.0)

Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; NDCMP, National Diabetes Care Management Program; NTD, New Taiwan dollar; OAD, oral antidiabetes drug; T2D, type 2 diabetes

[Table 2](#pmed.1003094.t002){ref-type="table"} shows the prevalence of individual conditions included in our multimorbidity total, concordant, and discordant counts. In the UK Biobank, 15,654 (76.1%) participants had at least one concordant condition, and 13,753 (66.9%) had at least one discordant condition in addition to T2D. In the Taiwan NDCMP, a slightly lower proportion of participants had at least one concordant condition (57.2%), and a similar proportion had at least one discordant condition compared (58.0%) with the UK Biobank. The most prevalent condition was hypertension, with a prevalence of 69.0% and 48.2%, respectively.

10.1371/journal.pmed.1003094.t002

###### Prevalence of individual multimorbid conditions in participants with T2D.

![](pmed.1003094.t002){#pmed.1003094.t002g}

  ----------------------------------------------------------------- ------------------------------- ---------------------------------
  **Presence of chronic conditions concordant with T2D, *n* (%)**   **UK Biobank (*N =* 20,569)**   **Taiwan NDCMP (*N =* 59,657)**
      At least one chronic condition concordant with diabetes       15,654 (76.1)                   34,111 (57.2)
      Hypertension                                                  14,187 (69.0)                   28,771 (48.2)
      Coronary heart disease                                        3,773 (18.3)                    8,639 (14.5)
      Peripheral vascular disease                                   488 (2.4)                       1,711 (2.9)
      Chronic kidney disease                                        323 (1.6)                       1,919 (3.2)
      Stroke/TIA                                                    1,024 (5.0)                     4,350 (7.3)
      Diabetic retinopathy                                          2,174 (10.6)                    1,494 (2.5)
      Diabetic neuropathy                                           74 (0.4)                        642 (1.1)
      Atrial fibrillation                                           641 (3.1)                       472 (0.8)
      Heart failure                                                 426 (2.1)                       1,394 (2.3)
  **Presence of chronic conditions discordant with T2D, *n* (%)**   **UK Biobank (*N =* 20,569)**   **Taiwan NDCMP (*N =* 59,657)**
      At least one chronic condition discordant with diabetes       13,753 (66.9)                   34,592 (58.0)
      Depression                                                    1,643 (8.0)                     628 (1.1)
      Painful conditions (excluding diabetic neuropathy)            6,250 (30.4)                    13,754 (23.1)
      Asthma                                                        2,959 (14.4)                    1,404 (2.4)
      Dyspepsia                                                     3,815 (18.5)                    12,297 (20.6)
      Thyroid disorders                                             1,688 (8.2)                     1,618 (2.7)
      Rheumatoid arthritis and other connective tissue disorders    618 (3.0)                       309 (0.5)
      COPD                                                          841 (4.1)                       4,000 (6.7)
      Anxiety                                                       509 (2.5)                       3,398 (5.7)
      Irritable bowel syndrome                                      500 (2.4)                       636 (1.1)
      Cancer                                                        2,110 (10.3)                    1,107 (1.9)
      Alcohol problems                                              427 (2.1)                       370 (0.6)
      Other psychoactive substance misuse                           13 (0.1)                        23 (0.0)
      Constipation                                                  288 (1.4)                       2,670 (4.5)
      Diverticular disease                                          1,056 (5.1)                     86 (0.1)
      Prostate disorders                                            890 (4.3)                       2,513 (4.2)
      Glaucoma                                                      458 (2.2)                       305 (0.5)
      Epilepsy                                                      211 (1.0)                       135 (0.2)
      Dementia                                                      10 (0.0)                        330 (0.6)
      Schizophrenia/bipolar disorder                                187 (0.9)                       380 (0.6)
      Psoriasis/eczema                                              792 (3.9)                       1,704 (2.9)
      Inflammatory bowel disease                                    924 (4.5)                       24 (0.0)
      Migraine                                                      306 (1.5)                       162 (0.3)
      Chronic sinusitis                                             176 (0.9)                       152 (0.3)
      Anorexia/bulimia                                              2 (0.0)                         148 (0.3)
      Bronchiectasis                                                56 (0.3)                        162 (0.3)
      Parkinson disease                                             42 (0.2)                        309 (0.5)
      Multiple sclerosis                                            71 (0.3)                        4 (0.0)
      Viral hepatitis                                               56 (0.3)                        1,263 (2.1)
      Chronic liver disease                                         326 (1.6)                       7,047 (11.8)
      Osteoporosis                                                  340 (1.7)                       1,322 (2.2)
      Chronic fatigue syndrome                                      71 (0.3)                        0 (0.0)
      Endometriosis                                                 162 (0.8)                       100 (0.2)
      Meniere disease                                               52 (0.3)                        493 (0.8)
      Pernicious anaemia                                            134 (0.7)                       31 (0.1)
      Polycystic ovary                                              31 (0.2)                        17 (0.0)
  ----------------------------------------------------------------- ------------------------------- ---------------------------------

Abbreviations: COPD, chronic obstructive pulmonary disease; NDCMP, National Diabetes Care Management Program; T2D, type 2 diabetes; TIA, transient ischaemic attack

[Table 3](#pmed.1003094.t003){ref-type="table"} shows the mean difference in HbA1c between participants with different multimorbidity counts. Participants with T2D only were the reference group. In both the UK Biobank and the Taiwan NDCMP, increasing total multimorbidity and discordant counts were associated with lower HbA1c. Notably, the mean difference in HbA1c was greater in the Taiwan NDCMP compared with the UK Biobank. For concordant conditions, associations between increasing concordant counts and lower HbA1c were only observed in the Taiwan NDCMP, whereas there was no association in the UK Biobank. In the sensitivity analysis, when physical activity was additionally adjusted for in the UK Biobank, the results were similar. However, when the number of outpatient visits was additionally adjusted for in the Taiwan NDCMP, the associations between all multimorbidity counts and HbA1c attenuated slightly ([S2 Table](#pmed.1003094.s004){ref-type="supplementary-material"}). When we used only the HES data to identify multimorbidity in the UK Biobank, the results for associations between multimorbidity and HbA1c were similar to our main analysis ([S4 Table](#pmed.1003094.s006){ref-type="supplementary-material"}).

10.1371/journal.pmed.1003094.t003

###### Multivariable linear regression model: Relationship between HbA1c and multimorbidity in participants with type 2 diabetes.

![](pmed.1003094.t003){#pmed.1003094.t003g}

                                                         UK Biobank   Taiwan NDCMP                                                                                                                             
  ------------------------------------------------------ ------------ ---------------------- --------- ---------------------- --------- -------------- ---------------------- --------- ---------------------- ---------
  Diabetes only (reference)                              79/1,918     Ref                              Ref                              1,493/12,950   Ref                              Ref                    
  Diabetes plus 1 chronic condition                      280/5,114    −0.07 (−0.14, −0.01)   0.024     −0.07 (−0.13, −0.01)   0.031     2,430/15,480   −0.49 (−0.54, −0.45)   \<0.001   −0.62 (−0.67, −0.58)   \<0.001
  Diabetes plus 2 chronic conditions                     421/5,109    −0.13 (−0.19, −0.06)   \<0.001   −0.12 (−0.18, −0.06)   \<0.001   3,318/15,139   −0.57 (−0.61, −0.52)   \<0.001   −0.72 (−0.76, −0.67)   \<0.001
  Diabetes plus 3 chronic conditions                     395/3,643    −0.11 (−0.17, −0.04)   0.002     −0.13 (−0.19, −0.06)   \<0.001   2,505/8,330    −0.55 (−0.61, −0.49)   \<0.001   −0.75 (−0.80, −0.69)   \<0.001
  Diabetes plus ≥4 chronic conditions                    759/4,785    −0.16 (−0.23, −0.10)   \<0.001   −0.20 (−0.26, −0.14)   \<0.001   3,477/7,753    −0.55 (−0.60, −0.49)   \<0.001   −0.82 (−0.88, −0.76)   \<0.001
  **Categories of diabetes and concordant conditions**                                                                                                                                                         
  Diabetes only (reference)                              79/1,918     Ref                              Ref                              1,493/12,950   Ref                              Ref                    
  Diabetes plus 1 concordant condition                   768/10,251   −0.14 (−0.20, −0.08)   \<0.001   −0.11 (−0.18, −0.06)   \<0.001   5,043/22,407   −0.59 (−0.63, −0.54)   \<0.001   −0.70 (−0.74, −0.65)   \<0.001
  Diabetes plus 2 concordant conditions                  507/3,867    −0.06 (−0.12, 0.01)    0.098     −0.10 (−0.16, −0.03)   0.003     2,950/8,865    −0.59 (−0.65, −0.54)   \<0.001   −0.74 (−0.80, −0.69)   \<0.001
  Diabetes plus 3 concordant conditions                  247/1,131    −0.07 (−0.15, 0.02)    0.153     −0.13 (−0.22, −0.04)   0.003     1,140/2,221    −0.58 (−0.67, −0.48)   \<0.001   −0.78 (−0.87, −0.69)   \<0.001
  Diabetes plus ≥4 concordant conditions                 129/402      0.05 (−0.07, 0.19)     0.417     −0.03 (−0.16, 0.09)    0.608     427/618        −0.38 (−0.55, −0.22)   0.029     −0.66 (−0.83, −0.50)   \<0.001
  **Categories of diabetes and discordant conditions**                                                                                                                                                         
  Diabetes only (reference)                              79/1,918     Ref                              Ref                              1,493/12,950   Ref                              Ref                    
  Diabetes plus 1 discordant condition                   574/6,387    −0.11 (−0.18, −0.06)   \<0.001   −0.11 (−0.17, −0.04)   \<0.001   4,187/19,177   −0.52 (−0.57, −0.48)   \<0.001   −0.68 (−0.73, −0.63)   \<0.001
  Diabetes plus 2 discordant conditions                  393/3,793    −0.14 (−0.20, −0.07)   \<0.001   −0.14 (−0.20, −0.08)   \<0.001   2,678/9,615    −0.52 (−0.58, −0.47)   \<0.001   −0.73 (−0.78, −0.67)   \<0.001
  Diabetes plus 3 discordant conditions                  246/1,951    −0.22 (−0.30, −0.14)   \<0.001   −0.20 (−0.28, −0.13)   \<0.001   1,335/3,770    −0.54 (−0.62, −0.47)   \<0.001   −0.81 (−0.89, −0.74)   \<0.001
  Diabetes plus ≥4 discordant conditions                 271/1,621    −0.19 (−0.27, −0.11)   \<0.001   −0.23 (−0.31, −0.15)   \<0.001   945/2,030      −0.48 (−0.57, −0.38)   \<0.001   −0.79 (−0.89, −0.70)   \<0.001

\*Adjusting for age, gender, BMI, smoking status, alcohol consumption, socioeconomic status, duration of diabetes, use of oral antidiabetes drugs, and use of corticosteroids.

Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; NDCMP, National Diabetes Care Management Program; Ref, reference

[Fig 1](#pmed.1003094.g001){ref-type="fig"} compares the unadjusted survival among the study participants on the basis of total multimorbidity, concordant, and discordant condition counts, respectively. For a given count of concordant conditions, mortality was higher (or survival lower) than for an equivalent count of discordant conditions or any conditions. Notably, in all three counts of multimorbidity (total, concordant, and discordant) the survival rate in the Taiwan NDCMP compared with the UK Biobank was much lower, with a steeper increase in proportion of death.

![Cumulative survival plot showing probability of all-cause mortality among type 2 diabetes participants with different levels of multimorbidity.\
(A) Total multimorbid conditions in UK Biobank; (B) concordant conditions in UK Biobank; (C) discordant conditions in UK Biobank; (D) total multimorbid conditions in Taiwan NDCMP; (E) concordant conditions in Taiwan NDCMP; (F) discordant conditions in Taiwan NDCMP. NDCMP, National Diabetes Care Management Program.](pmed.1003094.g001){#pmed.1003094.g001}

[Table 4](#pmed.1003094.t004){ref-type="table"} shows the unadjusted and adjusted HRs comparing categories of total, concordant, and discordant multimorbidity counts with T2D and all-cause mortality (with a reference group of those with T2D only). In both the UK Biobank and the Taiwan NDCMP, increasing total, concordant, and discordant multimorbidity counts were all significantly associated with increased all-cause mortality. In the UK Biobank, the HRs (95% CI) for having one, two, three, and four or more total multimorbidity conditions compared with those with T2D only were 1.20 (0.91--1.56) *p \<* 0.001, 1.75 (1.35--2.27) *p \<* 0.001, 2.17 (1.67--2.81) *p \<* 0.001, and 3.14 (2.43--4.03) *p \<* 0.001, respectively. The HRs for the Taiwan NDCMP were slightly lower yet still statistically significant. For the Taiwan NDCMP, the HRs (95% CI) for having one, two, three, and four or more total multimorbidity conditions compared with those with T2D only were 1.17 (1.09--1.25) *p \<* 0.001, 1.39 (1.30--1.48) *p \<* 0.001, 1.79 (1.67--1.92) *p \<* 0.001, and 2.50 (2.34--2.67) *p \<* 0.001, respectively.

10.1371/journal.pmed.1003094.t004

###### Cox's proportional hazards model: Relationship between all-cause mortality and multimorbidity in participants with type 2 diabetes.

![](pmed.1003094.t004){#pmed.1003094.t004g}

                                                         UK Biobank   Taiwan NDCMP                                                                                                                   
  ------------------------------------------------------ ------------ -------------------- --------- ------------------- --------- -------------- -------------------- --------- ------------------- ---------
  Diabetes only (reference)                              79/1,918     1                              1                             1,493/12,950   1                              1                   
  Diabetes plus 1 chronic condition                      280/5,114    1.33 (1.04--1.71)    0.024     1.20 (0.91--1.56)   \<0.001   2,430/15,480   1.38 (1.29--1.47)    \<0.001   1.17 (1.09--1.25)   \<0.001
  Diabetes plus 2 chronic conditions                     421/5,109    2.04 (1.61--2.60)    \<0.001   1.75 (1.35--2.27)   \<0.001   3,318/15,139   2.00 (1.88--2.13)    \<0.001   1.39 (1.30--1.48)   \<0.001
  Diabetes plus 3 chronic conditions                     395/3,643    2.73 (2.14--3.48)    \<0.001   2.17 (1.67--2.81)   \<0.001   2,505/8,330    2.90 (2.72--3.01)    \<0.001   1.79 (1.67--1.92)   \<0.001
  Diabetes plus ≥4 chronic conditions                    759/4,785    4.14 (3.28--5.22)    \<0.001   3.14 (2.43--4.03)   \<0.001   3,477/7,753    4.89 (4.60--5.20)    \<0.001   2.50 (2.34--2.67)   \<0.001
  **Categories of diabetes and concordant conditions**                                                                                                                                               
  Diabetes only (reference)                              79/1,918     1                              1                             1,493/12,950   1                              1                   
  Diabetes plus 1 concordant condition                   768/10,251   1.84 (1.46--2.32)    \<0.001   1.58 (1.23--2.03)   \<0.001   5,043/22,407   2.06 (1.95--2.18)    \<0.001   1.42 (1.33--1.51)   \<0.001
  Diabetes plus 2 concordant conditions                  507/3,867    3.35 (2.64--4.24)    \<0.001   2.41 (1.87--3.13)   \<0.001   2,950/8,865    3.29 (3.09--3.50)    \<0.001   1.87 (1.75--2.00)   \<0.001
  Diabetes plus 3 concordant conditions                  247/1,131    5.90 (4.58--7.61)    \<0.001   4.00 (3.03--5.27)   \<0.001   1,140/2,221    5.94 (5.50--6.42)    \<0.001   2.80 (2.58--3.05)   \<0.001
  Diabetes plus ≥4 concordant conditions                 129/402      9.51 (7.18--12.58)   \<0.001   5.83 (4.28--7.93)   \<0.001   427/618        9.83 (8.83--10.95)   \<0.001   3.79 (3.38--4.25)   \<0.001
  **Categories of diabetes and discordant conditions**                                                                                                                                               
  Diabetes only (reference)                              79/1,918     1                              1                             1,493/12,950   1                              1                   
  Diabetes plus 1 discordant condition                   574/6,387    2.23 (1.77--2.83)    \<0.001   1.89 (1.46--2.43)   \<0.001   4,187/19,177   1.99 (1.88--2.11)    \<0.001   1.42 (1.33--1.51)   \<0.001
  Diabetes plus 2 discordant conditions                  393/3,793    2.62 (2.06--3.33)    \<0.001   2.09 (1.61--2.71)   \<0.001   2,678/9,615    2.64 (2.48--2.81)    \<0.001   1.64 (1.54--1.76)   \<0.001
  Diabetes plus 3 discordant conditions                  246/1,951    3.22 (2.50--4.14)    \<0.001   2.58 (1.95--3.40)   \<0.001   1,335/3,770    3.59 (3.34--3.87)    \<0.001   2.05 (1.89--2.22)   \<0.001
  Diabetes plus ≥4 discordant conditions                 271/1,621    4.39 (3.42--5.64)    \<0.001   3.50 (2.65--4.62)   \<0.001   945/2,030      5.17 (4.76--5.61)    \<0.001   2.62 (2.40--2.86)   \<0.001

\*Adjusting for age, gender, BMI, smoking status, alcohol consumption, socioeconomic status, baseline HbA1c, duration of diabetes, use of oral antidiabetes drugs, and use of corticosteroids.

Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; HR, hazard ratio; NDCMP, National Diabetes Care Management Program

For concordant conditions, the HRs were larger compared with the HRs observed for total multimorbidity counts. In the UK Biobank, the HRs (95% CI) for having one, two, three, and four or more concordant conditions compared with those with T2D were 1.58 (1.23--2.03) *p \<* 0.001, 2.41 (1.87--3.13) *p \<* 0.001, 4.00 (3.03--5.27) *p \<* 0.001, and 5.83 (4.28--7.93) *p \<* 0.001, respectively. Again, the HRs for the Taiwan NDCMP were slightly lower yet still statistically significant. For the Taiwan NDCMP, the HRs (95% CI) for having one, two, three, and four or more concordant conditions compared with those with T2D were 1.42 (1.33--1.51) *p \<* 0.001, 1.87 (1.75--2.00) *p \<* 0.001, 2.80 (2.58--3.05) *p \<* 0.001, and 3.79 (3.38--4.25) *p \<* 0.001, respectively.

For discordant conditions, the HRs were smaller compared with the HRs observed for both total multimorbidity and concordant counts. In the UK Biobank, the HRs (95% CI) for having one, two, three, and four or more discordant conditions were 1.89 (1.46--2.43) *p \<* 0.001, 2.09 (1.61--2.71) *p \<* 0.001, 2.58 (1.95--3.40) *p \<* 0.001, and 3.50 (2.65--4.62) *p \<* 0.001, respectively. The HRs for the Taiwan NDCMP were slightly lower yet still statistically significant. For the Taiwan NDCMP, the HRs (95% CI) for having one, two, three, and four or more discordant conditions were 1.42 (1.33--1.51) *p \<* 0.001, 1.64 (1.54--1.76) *p \<* 0.001, 2.05 (1.89--2.22) *p \<* 0.001, and 2.62 (2.40--2.86) *p \<* 0.001, respectively.

For all the mortality analyses for the UK Biobank, the sensitivity analysis further adjusted for physical activity, whereas in the Taiwan NDCMP, further adjustment was made for number of outpatient visits. The sensitivity analyses made little difference to the associations between all counts of multimorbidity and mortality ([S3 Table](#pmed.1003094.s005){ref-type="supplementary-material"}). When we used only the HES data to identify multimorbidity in the UK Biobank, the results for associations between multimorbidity and all-cause mortality were similar to our main analysis ([S4 Table](#pmed.1003094.s006){ref-type="supplementary-material"}).

Figs [2](#pmed.1003094.g002){ref-type="fig"}, [3](#pmed.1003094.g003){ref-type="fig"}, [4](#pmed.1003094.g004){ref-type="fig"} and [5](#pmed.1003094.g005){ref-type="fig"} compare the adjusted HRs of the presence of individual concordant (Figs [2](#pmed.1003094.g002){ref-type="fig"} and [3](#pmed.1003094.g003){ref-type="fig"}) and discordant conditions (Figs [4](#pmed.1003094.g004){ref-type="fig"} and [5](#pmed.1003094.g005){ref-type="fig"}) (\>1% prevalence) on mortality. All concordant conditions with the exception of diabetic retinopathy (in the UK Biobank) and diabetic neuropathy (in the Taiwan NDCMP) showed significant associations with increased mortality. Presence of heart failure (HF) had the largest HR in both datasets, with HR (95% CI) of 3.24 (2.69--3.91) *p \<* 0.001 in the UK Biobank. Following HF, the presence of peripheral vascular disease (PVD), chronic kidney disease (CKD), and atrial fibrillation (AF) is associated with greater than 2-fold the risk of mortality in the UK Biobank. Similarly, both HF and CKD are also associated with greater than 2-fold the risk of mortality in the Taiwan NDCMP.

![Forest plot of HR for the presence of different concordant conditions (prevalence \>1%) and all-cause mortality in participants with type 2 diabetes in UK Biobank.\
HR, hazard ratio; No., number; TIA, transient ischaemic attack.](pmed.1003094.g002){#pmed.1003094.g002}

![Forest plot of HR for the presence of different concordant conditions (prevalence \>1%) and all-cause mortality in participants with type 2 diabetes in Taiwan NDCMP.\
HR, hazard ratio; NDCMP, National Diabetes Care Management Program; No., number; TIA, transient ischaemic attack.](pmed.1003094.g003){#pmed.1003094.g003}

![Forest plot of HR for the presence of different discordant conditions (prevalence \>1%) and all-cause mortality in participants with type 2 diabetes in UK Biobank.\
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![Forest plot of HR for the presence of different discordant conditions (prevalence \>1%) and all-cause mortality in participants with type 2 diabetes in Taiwan NDCMP.\
COPD, chronic obstructive pulmonary disease; HR, hazard ratio; NDCMP, National Diabetes Care Management Program.](pmed.1003094.g005){#pmed.1003094.g005}

Among discordant conditions, presence of alcohol problems (alcohol dependency, alcoholic liver disease/alcoholic cirrhosis) (HR 2.58, 95% CI 2.07--3.21, *p \<* 0.001), chronic liver disease (HR 2.29, 95% CI 1.75--3.01, *p \<* 0.001), chronic obstructive pulmonary disease (COPD) (HR 2.00, 95% CI 1.69--2.36, *p \<* 0.001), and cancer (HR 1.79, 95% CI 1.58--2.04, *p \<* 0.001) had the largest HRs in the UK Biobank, all of which were associated with greater than 1.5-fold the risk of mortality, whereas presence of cancer (HR 2.25, 95% CI 2.06--2.45, *p \<* 0.001) and viral hepatitis (HR 2.00, 95% CI 1.81--2.20, *p \<* 0.001) had the largest HRs in the Taiwan NDCMP.

Figs [6](#pmed.1003094.g006){ref-type="fig"} and [7](#pmed.1003094.g007){ref-type="fig"} compare the adjusted HRs of the presence of the top 20 combinations (by effect size) of two conditions and all-cause mortality in the UK Biobank ([Fig 6](#pmed.1003094.g006){ref-type="fig"}) and the Taiwan NDCMP ([Fig 7](#pmed.1003094.g007){ref-type="fig"}). Cardiovascular diseases are present in 18 of the top 20 combinations on mortality in the UK Biobank, whereas in the Taiwan NDCMP, cardiovascular diseases are present in 12 of the top 20 combinations on mortality. In the UK Biobank, a combination of coronary heart disease (CHD) and HF had the largest effect size on mortality, with HR (95% CI) of 4.37 (3.59--5.32) *p \<* 0.001. Following the combination of CHD and HF, the CHD--CKD and HF--dyspepsia combinations are each associated with greater than 4-fold the risk of mortality in the UK Biobank. The remaining top 20 combinations of conditions in the UK Biobank had greater than 2.5-fold risk of mortality. In the Taiwan NDCMP, a combination of painful conditions and alcohol problems had the largest effect size on mortality, with HR (95% CI) of 4.02 (3.08--5.23) *p \<* 0.001. Following that, combinations of dyspepsia and alcohol problems, cancer and chronic liver disease, alcohol problems and chronic liver disease, and HF and asthma are associated with greater than 3-fold the risk of mortality. The remaining top 20 combinations of conditions in the Taiwan NDCMP had greater than 2-fold risk of mortality.

![Forest plot of HR for the presence of the top 20 combinations (by effect size) of two conditions and all-cause mortality in participants with type 2 diabetes in UK Biobank.\
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Discussion {#sec015}
==========

In this study, comprising more than 80,000 middle-aged and older-aged people from two national datasets, we identified that multimorbidity was highly prevalent among people with T2D. More than 80% were found to have at least one other chronic condition in addition to T2D. We found that the associations between multimorbidity, HbA1c, and mortality are similar across two separate cohorts from two countries with different healthcare systems and differing ethnicities. Increasing total multimorbidity and discordant condition counts were associated with slightly lower HbA1c. We found significant associations between increasing multimorbidity and risk of mortality. This finding was consistent for total count of multimorbidity as well as counts of concordant and discordant conditions. This association was strongest for increasing concordant conditions. Each concordant condition, except diabetic retinopathy and neuropathy, was associated with significantly higher risk of mortality, and the presence of HF, PVD, CKD, and AF had the largest effect sizes. Presence of certain discordant conditions (alcohol problems, chronic liver disease, COPD, cancer, and viral hepatitis) had similar risk of mortality compared with concordant conditions. Our findings also show that cardiovascular diseases play a significant role in the increased mortality seen in those with multimorbidity because such conditions were in 18 of the top 20 combinations (by effect size) of two conditions in UK Biobank, whereas they were present in 12 of the top 20 combinations in the Taiwan NDCMP. We have also shown that there are key differences in the top combinations (by effect size) of two conditions in addition to T2D associated with increased risk of death between the two cohorts.

Our results indicate that increasing total multimorbidity and discordant counts were associated with lower HbA1c. This adds to the existing literature and a recent systematic review, findings from which showed mixed results in terms of the associations between multimorbidity and HbA1c \[[@pmed.1003094.ref007]\]. This is particularly interesting because it has been established that achievement of HbA1c targets is a key component of T2D management and is important in reducing all-cause mortality \[[@pmed.1003094.ref015]\]. Although studies have also noted associations between low HbA1c and increased mortality, the causal link between the two remains unclear \[[@pmed.1003094.ref016],[@pmed.1003094.ref017]\]. The slightly lower HbA1c observed in our study aligns with a previous study that showed that those who live with more chronic conditions receive better quality of care and higher health service use, leading to more opportunities for care of multimorbidity conditions \[[@pmed.1003094.ref018]\]. This could also mean earlier diagnosis of the range of conditions they are living with. For example, those that have heart disease could be diagnosed earlier, meaning they are more likely to have HbA1c tests that are only mildly elevated, and subsequently receive treatment earlier. In light of this, our sensitivity analyses in the Taiwan NDCMP, in which the inclusion of the number of outpatient visits attenuated the association between multimorbidity and HbA1c, suggests that higher health service utilisation may play a role in glycaemic management in those with T2D living with multimorbidity. Furthermore, another possible explanation of the lower HbA1c seen in our results is that of survival bias. In the UK Biobank, those who live with more chronic conditions (higher degree of multimorbidity) and a higher HbA1c may not be well enough or alive to attend the baseline assessment and, hence, unable to participate in the UK Biobank; however, this would not explain the similar findings in the Taiwan dataset.

Although our results indicate associations between increasing multimorbidity and slightly lower HbA1c, a major caveat is that the degree of difference observed in HbA1c (ranging from −0.07% to −0.82%) seen in our results is not likely to be clinically significant despite being statistically significant. There have been discussions around what degree of reduction in HbA1c could be seen as clinically significant; however, it would be patient dependent \[[@pmed.1003094.ref019]\]. Not all HbA1c improvements are equal in regard to clinical benefit; for example, a reduction of 1% in HbA1c offers different benefits if the improvement was from 12% to 11% compared with 7% to 6%. Furthermore, it is generally regarded that it is easier for patients with poorer glycaemic control to reduce their HbA1c (for example, from 10% to 9%) than for patients with relatively good glycaemic control. Although the UK Biobank cohort represents a relatively healthy population with good glycaemic control in which the mean (SD) HbA1c was 6.8 (1.2)%, it is important to note that the results were similar in the Taiwan NDCMP cohort, which is a population cohort in which the mean (SD) HbA1c was 8.2 (2.0)%.

Our study findings are consistent with previous literature in which increasing multimorbidity counts are significantly associated with higher mortality in people with T2D \[[@pmed.1003094.ref007]\]. However, it is the first to assess the implications of concordant versus discordant multimorbidity counts and the associations between individual conditions and mortality. Only one study has assessed the type of condition in multimorbidity by differentiating between physical and mental health conditions \[[@pmed.1003094.ref008]\]. Evidence suggests that those with more concordant conditions have improved diabetes care because of synergistic care, in which diabetes guidelines often make specific recommendations for concordant conditions but do not address discordant conditions \[[@pmed.1003094.ref005],[@pmed.1003094.ref020]\]. As a result, to date it has been suggested that those with discordant conditions may have suboptimal care because of competition for limited resources and distraction from diabetes care, which could ultimately lead to worse outcomes and increased mortality \[[@pmed.1003094.ref005],[@pmed.1003094.ref021]\]. Our study contributes to understanding of which patterns of multimorbidity are associated with poorer outcomes \[[@pmed.1003094.ref005],[@pmed.1003094.ref007]\] and demonstrates that both concordant and discordant conditions are associated with mortality but that discordant conditions generally have lower risks of death. However, we show that particular discordant conditions, such as alcohol problems, chronic liver disease, COPD, and cancer, have equal risk of mortality to concordant conditions. We also contribute to the understanding of patterns of multimorbidity that are associated with poorer outcomes in different ethnic groups through exploring associations between the top combinations of conditions and mortality in a predominantly white population (UK Biobank) and predominantly ethnic Chinese one (Taiwan NDCMP cohort). Our findings show that cardiovascular diseases are present in the majority of the top combinations that are associated with the highest risk of death in both cohorts, consistent with previous literature \[[@pmed.1003094.ref022],[@pmed.1003094.ref023]\]. Importantly, although we have noted the significant contributions of cardiovascular diseases to increased mortality, particularly in the UK Biobank population, our findings also suggest that certain combinations of discordant conditions are also strongly associated with increased mortality. This was particularly marked in the Taiwan NDCMP cohort, in which alcohol problems, chronic liver disease, cancer, painful conditions, and dyspepsia were in the top four combinations (by effect size) of two conditions associated with increased risk of death, whereas only dyspepsia featured as part of a combination in the top five combinations in UK Biobank. This highlights the need for further research to consider the importance of ethnic differences when considering the implications of multimorbidity in people with T2D. It also underscores the importance of personalised care that takes account of individual characteristics, including ethnicity, along with number and type of conditions when managing those with T2D living with multimorbidity. Current guidelines do acknowledge the complex nature of multimorbidity, for which the choice of glycaemic targets and treatment should be based on the patient's individual clinical needs, comorbidities, and the risks from polypharmacy \[[@pmed.1003094.ref024]\]. Therefore, it is important to consider the overall multimorbidity disease burden as a way of recalibrating and personalising our clinical focus in managing people with T2D \[[@pmed.1003094.ref025]\]. However, future studies should aim to explore the mechanisms underpinning the increased mortality and lower HbA1c associated with multimorbidity observed in our findings. This could contribute to better understanding of how to manage specific patterns of multimorbidity and how this should be balanced across the treatment of all multimorbidity conditions. Better understanding of these issues, including effects of condition type, will enable more effective personalisation of care for those with T2D and multimorbidity.

To our knowledge, this is the first study to assess and compare the relationship between total, concordant, and discordant multimorbidity counts; HbA1c; and all-cause mortality in people with T2D. We also show the associations of a wide range of individual conditions included in our multimorbidity counts and mortality. Our study is also novel in that we explored combinations of conditions that were associated with the highest risk of death. Key strengths include use of two national datasets, large sample sizes, recruitment from the UK and Taiwan, and adjustment of our analyses for a wide range of sociodemographic and lifestyle factors. We utilised a robust method to capture multimorbidity conditions using both self-report data and coded hospital data. However, these data were only available at baseline, and we were unable to model for changes in multimorbidity over our study period. Therefore, a limitation of our study is that we were unable to consider the temporality and duration of the conditions in addition to diabetes, which is important for serious conditions such as stroke, TIA, and cancer. UK Biobank is not a random population sample: the participants are more likely to be people of European descent and comparatively less deprived socioeconomically compared with the general UK population \[[@pmed.1003094.ref026]\], suggesting that our findings are likely to be conservative regarding the prevalence of multimorbidity and its associations with mortality. A limitation to note is that despite depression being increasingly common in those with T2D, there was a comparatively low prevalence of depression in our Taiwan NDCMP cohort. However, this is consistent with evidence suggesting the prevalence of depression is significantly lower in Asia Pacific countries compared with western European countries\[[@pmed.1003094.ref027]\], perhaps because of underdiagnosis of depression due to cultural and social stigma associated with mental health conditions in Asian countries \[[@pmed.1003094.ref028]\]. Although we have classified mental health conditions including depression and anxiety as discordant conditions, there are still debates regarding whether this is appropriate. Studies have shown that depression and anxiety may share biological and behavioural mechanisms \[[@pmed.1003094.ref029]\], which could mean that our classification of these conditions could lead to underestimating the associations between concordant conditions and our outcomes. There was a large overlap between the concordant and discordant condition groups, so a limitation of our study was that for cases in which a person lives with both concordant and discordant conditions, we did not explore this overlap and the individual effects of the two condition groups on HbA1c and mortality. Furthermore, we also did not explore the overlap of the effects of individual conditions within the same condition group; for example, the overlap between chronic liver diseases and alcohol problems. Finally, the fact that the 35 conditions considered in our discordant conditions count included many that are not strong predictors of death may have diluted the overall relationship between discordant condition count and mortality.

In conclusion, increasing multimorbidity is significantly associated with increased mortality in those with T2D and with lower HbA1c. This was observed in two large community cohorts of people from different healthcare systems. The highest risk of mortality is seen in those with concordant conditions, but discordant conditions such as alcohol problems, chronic liver disease, and COPD in UK Biobank and cancer and viral hepatitis in the Taiwan NDCMP cohort were still associated with more than 2-fold the risk of mortality. A key finding is that the combinations of conditions with the greatest association with mortality differed between UK Biobank, a population predominantly comprising people of European descent, and the Taiwan NDCMP, a predominantly ethnic Chinese population. These findings suggest that we need to know more about the influence of different patterns of multimorbidity on outcomes across different ethnic groups in T2D populations. Furthermore, a more cautious approach to tight glycaemic control in some patterns of multimorbidity and T2D may merit consideration. However, further research is needed to explore the mechanisms underpinning these findings. It will be important for clinicians to better understand the biology or healthcare delivery approaches that are contributing to these associations in order to tailor advice to better meet the needs of these diverse and complex populations of people with T2D from different ethnic backgrounds.
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Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

The abstract is written is a slightly 'listy' way with headings of outcomes etc. Please remove and write in a more traditional style and avoid short statements such as 'Baseline HbA1c; all-cause mortality'; as the final sentence of the 'Methods and findings' section please add a sentence or 2 on the limitations of the study; please add p values where 95%Cis are given; please add some baseline demographic information on the participants in the cohorts;

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please

see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

Square brackets for refs in main text -- please place these before the punctuation. And when occurring mid-sentence please insert a space before the open bracket.

The use of MM throughout -- as this probably generates lots of returns in PubMed searches please avoid using MM. I also think co-morbidity is a more commonly used phrase? So in any case remove 'MM' throughout, please and consider instead co-morbidity (spelt out in full and not as CM). Further to this, in both the abstract and main text on first mention, can you please list what these other conditions are or at least the major ones.

Please avoid use of quote marks ("") for emphasis or quoting other papers.

Line 133 -- can you clarify what light 'do-it-yourself (DIY)' activity only in the last 4week means? Are you defining exercise for this category as only doing DIY? It reads oddly to say exercise is DIY.

Table 3, please remove 'present'after diabetes and write as 'diabetes plus....' (also for Table 4 and any other similar occurences, please).

Fig 1 -- add a time scale (dates) to the X axis in all panels

Main text -- please add p values with Cis

As Ref 3 also mentions, please avoid causal language as this is not a trial.

STROBE checklist -- thank you for supplying -- please also add the paragraph numbers to the sections.

Comments from the reviewers:

Reviewer \#1: I confine my remarks to statistical aspects of this paper. I have a couple general questions:

1\. Why treat count independent variables as if they were nominal? Even with the \"4 or more\" category, it is at least ordinal. Ordinal IVs are a bit tricky, but one method is optimal scaling. In SAS this is avaiable in PROC TRANSREG. In R, there is the optiscale package. But, since you have the actual count, you could treat it as continuous and maybe use a spline to see if there are nonlinearities.

2\. Although it isn\'t necessary, I think it would be very interesting to see if the effects of comorbities are additive or not, at least for the more common examples. That is, is the increased risk of death for people with T2D and CHD equal to the increase from T2D PLUS the increase from CHD? Or is it more? Or less? (This would require a normative sample \.... it might even be a different paper).

Specific comments

Line 120 - why group 4 or more? It\'s OK for tables, but not a great idea for models (see above)

Line 125-126 Don\'t categorize BMI. Categorizing continuous variables is almost always a mistake. I wrote about this here: <https://medium.com/@peterflom/what-happens-when-we-categorize-an-independent-variable-in-regression-77d4c5862b6c?source=friends_link&sk=1428cd15968e218268121dc507ce8025> and here <https://medium.com/@peterflom/why-binning-continuous-data-is-almost-always-a-mistake-ad0b3a1d141f?source=friends_link&sk=1d12e016e9dee55f273d38ab6258fb22>

Similar issues for amount of premium in Taiwan

Line 130 - why group current and former smokers?

Line 131-132 - if this is how the data were collected on alcohol, well \... then there isn\'t much you can do. But surely risk increases a lot at the high end (people who binge driink or drink many drinks per day)

Line 138-139 - same sort of question as above.

Line 143 - maybe I am misunderstanding something, but how is baseline HbA1c an outcome?

Table 1, 2 : Give median and IQR for BMI

The order of alcohol in table 1 is odd

For the IQR for duration, give it as 2 numbers (e.g 2 to 10). This is much more informative

Table 3 strikes me as very weird. However, given that the mean HbA1c was 6.8, are any of these differences substantively meaningful? (I know some are significant \.... but is 6.75 really different from 6.85 in any important way?

Figures - I would label the curves on the right hand margin with 0, 1, 2, 3, 4+ That seems more readable.

Reviewer \#2: This paper examines the mortality and HbA1c in people with type 2 diabetes and multimorbidity. This is a highly relevant research question given the rapidly raising number of people with diabetes and multimorbidity, and the novelty of the topic.

The strengths of the study include two large cohorts from two countries with two different healthcare systems and different ethnicities, combined with extended follow-up durations. The authors found that increasing total MM and discordant condition counts were associated with slightly lower HbA1c and significant associations between increasing MM and risk of mortality, which was consistent for total count of MM, as well as counts of, concordant and discordant conditions.

The manuscript is clearly and succinctly written and addresses a novel aspect of a subject of increasing interest and importance, and of notable clinical relevance. Nonetheless, I would say the results are less surprising, I have the following concerns:

1\. The conditions for the UK Biobank was ascertained either by self-reported or linked hospital data. This means that other conditions were assessed imprecisely and a large proportion of diabetes cases were missed as the ascertainment method did not include undiagnosed diabetes. It is unclear how this affects on study conclusion. I suggest the author re-run the models by using verified hospital cases to see whether the results were the same as combing both self-reported and hospital verified data.

2\. Although the authors adjusted the duration of the diabetes, what about the duration of other conditions? This is very important for some fatal conditions, for example, cancer, stork and TIA, which may take into account the competing risk, that is, the higher mortality risk in patients with diabetes and these conditions was because these conditions were the first occurring ones, and diabetes was a secondary one.

3\. Although there was some evidence to support the classification of these conditions into concordant and discordant, it\'s still controversial for some, for example, depression and anxiety, many studies suggest that these mental disorders and diabetes shared some common pathways. The discussion of this point and the potential resulting limitations should be expanded upon in the \"Strengths and limitations\" section of the Discussion.

4\. The prevalence of concordant and discordant conditions in the UK Biobank were 76.1% and 66.9% separately, there is a huge overlap between the two condition groups. However, it seems the authors did not explain what happened and how to deal with this overlap. If one give person has suffered from both concordant and discordant conditions, can the author figure out the effect on the HbA1c and mortality from which condition group? Furthermore, there are also overlaps among the included discordant conditions, for example, it\'s obvious that many people with alcohol problems would develop chronic liver diseases, depression and other conditions. It means the effects of alcohol problems may from other conditions.

5\. The authors mentioned the importance to look at the effect of multimorbidity patterns in patients with diabetes. Considering the big sample size, can the author explore which pattern is more harmful in patients with diabetes, but not only analysing the counts of conditions, which would be very interesting for clinical practice and disease control and prevention.

6\. Lines 212-214, these results (For a given count of concordant conditions, mortality was higher (or survival lower) than for an equivalent count of discordant conditions or any conditions) were not from the same model, can we compare them in such way?

7\. There is a special issue at the journal, it would be valuable to read these papers: <https://collections.plos.org/cvd-special-issue>

Reviewer \#3: Main points / suggestions

The strengths of this paper are the use of two very large datasets and a breakdown of different types of multi morbidity.

Main suggestion - I suggest the authors discuss more the possible reasons behind the apparently paradoxical association with increased MM and lower HbA1c. For example the authors make little mention of survival bias. One possible reason they see consistent associations between more diseases and lower hba1c is that those with more conditions were more likely have died or be too sick to participate in the studies. They describe the mortality effect nicely but don\'t appear to make the link. This is important to acknowledge because it means some conclusions need to be reworded eg \"these findings suggest a more cautious approach to tight glycaemic control in some MM in type 2 diabetes may be warranted.\" Although they mention another possibilty - better care, but they also do not explicitly mention possible better and earlier diagnosis - for example people with a heart condition will be tested for HbA1c, and so mild HbA1c is more likely to be picked up as well as treated.

other suggestions:

2\. it would be useful to add non diabetic frequencies of conditions and repeat analyses limited to conditions significant (at p\<0.05/42 conditions ) more freq in diabetes. This will help the reader assess whether or not some conditions are prsent in people with diabetes by chance, at similar frequuences as the general population.

3\. the tables dont include numbers of deaths. These Ns would be useful to add.

4\. consider using the new HbA1c scale.

5\. Take care with causal language- statements such as \"have effects on mortality\" should be reworded as \"associated with mortality\"

6\. Take care with multivariable vs multivariate (sensitivity analyses in methods)

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003094.r002

Author response to Decision Letter 0

29 Jan 2020

###### 

Submitted filename: Letter Response to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003094.r003
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Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

18 Feb 2020

Dear Dr. Chiang,

Thank you very much for re-submitting your manuscript \"Multimorbidity in Type 2 Diabetes: Associations With Mortality and HbA1c in Two Population Cohorts (UK and Taiwan)\" (PMEDICINE-D-19-03306R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by xxx reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Feb 25 2020 11:59PM.

Sincerely,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Title- to conform to house style, we suggest a change from Multimorbidity in Type 2 Diabetes: Associations With Mortality and HbA1c in Two Population 2 Cohorts (UK and Taiwan)

To

Multimorbidity with type 2 diabetes and associations between mortality and HbA1c: a cohort study with UK and Taiwanese cohorts.

It would be beneficial to emphasize the context a little more, perhaps ie "Evidence suggests that those with more concordant conditions have improved diabetes care due to synergistic care, where diabetes guidelines often make specific recommendations for concordant conditions but do not address discordant conditions \[5, 26\]". Please highlight this context a tad more- in the abstract and earlier in the conclusion section.

Page 19- there are a few sentences line 306, 311 and 316 where you say "The

306 HRs for the Taiwan NDCMP were slightly lower yet still statistically significant". The results are in Table 4 but I wonder why UK biobank results are called out and not the Taiwanese results? Please cite Table 4 in this section a bit more since that\'s where all the numbers are.

Please add summary demographic information to the abstract. I realise you added age already but can you say how many men, women for example and also things like how many are obese or smokers, etc.

I would suggest removing DIY. Thank you for the previous clarification around this term. You define it as chores such as mowing the lawn, so I think as DIY is used to define tasks like woodwork and building things, id stick to light or more heavy-duty household or garden tasks. Also at lines 202-205.

In the Author Summary, please remove the text from the author instx, such as "We ask authors to provide 2-3 single sentence bullet points for each of the following questions. 71 Bullet points should be objective, brief, succinct, specific, accurate, and avoid technical language. 72 Why Was This Study Done? Authors should reflect on what was known about the topic before the 73 research was published and why the research was needed." We only need the actual bullet points, but you have provided too many. We need 2-3 bullet points for each of the 3 sections.

Line 346 "alcohol problems" please define accurately

There appear to be different fonts in the text -- please be consistent (eg line 432)

Comments from Reviewers:

Reviewer \#1: The authors have addressed my concerns and I now recommend publication

Peter Flom

Reviewer \#3: THe authors have responded well to my suggestions. I would still prefer them to mention in the discussion more explicitly that the apparently paradoxical association between lower HbA1c and higher multimorbidity could be due to surivival or similar collider type biases. The individuals in the UK biobank study had an average age of 58 at the time of HbA1c measurment. At this average age it is likely that people with type 2 diabetes and multiple additional conditions \"need\" to have less severe diabetes compared to those with no other conditions, to be alive and well enough to participate in the study.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003094.r004

Author response to Decision Letter 1

8 Apr 2020
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10 Apr 2020

Dear Dr. Chiang,

On behalf of my colleagues and the academic editor, Dr. Ronald C.W. Ma, I am delighted to inform you that your manuscript entitled \"Multimorbidity, mortality and HbA1c in type 2 diabetes: a cohort study with UK and Taiwanese cohorts\" (PMEDICINE-D-19-03306R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: The authors have declared that no competing interests exist.
